Financial Performance - Net sales for the three months ended October 31, 2024, increased 13.6% to 377.1millioncomparedto332.0 million in the same period in the prior year[96]. - Gross margin increased 10.5% to 189.7million,butasapercentageofnetsales,itdecreasedto50.318.9 million, representing 5.0% of net sales, driven by the acquisition of Gravotech and increased headcount[98]. - SG&A expenses increased 16.2% to 111.8million,accountingfor29.758.9 million, with a margin of 15.6%, impacted by acquisition-related costs[102]. - Net income for the three months ended October 31, 2024, was 46.8million,adecreasefrom47.2 million in the same period in the prior year[103]. Cash Flow and Liquidity - The company had cash of 145.7millionandtotalavailableliquidityof1,182.2 million as of October 31, 2024, supporting growth strategies[91]. - Cash and cash equivalents decreased by 104.5millionto145.7 million as of October 31, 2024, with net cash provided by operating activities at 23.4million,downfrom62.3 million in the prior year[119]. - Net cash used in investing activities was 147.9million,mainlyforbusinessacquisitionstotaling140.6 million and capital expenditures of 7.3million[120].−TheoutstandingbalanceontheCompany′screditagreementwas116.6 million as of October 31, 2024, with a maximum outstanding amount of 144.8millionduringthequarter[127].−TheCompanymaintainedadebttoEBITDAratioof0.4to1.0andaninterestexpensecoverageratioof83.8to1.0,incompliancewithfinancialcovenants[128].−TheCompanyanticipatesthatcashflowfromoperatingactivitiesandborrowingcapacitywillbesufficienttomeetitsliquidityandcapitalneedsforthenext12months[118].SalesGrowth−Organicsalesgrew3.6245.4 million for the three months ended October 31, 2024, compared to 221.6millioninthesameperiodin2023,drivenbyorganicsalesgrowthof5.154.9 million, with a segment profit margin of 22.4%, essentially flat compared to 22.5% in the prior year[112]. - Europe & Australia net sales increased by 19.3% to 131.6million,withacquisitiongrowthcontributing15.013.1 million, with a profit margin dropping to 10.0% from 15.2% in the prior year, primarily due to acquisition-related costs[117]. - Organic sales in the Americas and Asia increased in the mid-single digits, with strong growth in product identification and safety product lines[110][111]. Future Outlook - The company anticipates continued easing of inflationary pressures and improved supply chain stability into fiscal 2025[89]. - Key initiatives for fiscal 2025 include enhancing R&D processes and expanding sales capabilities through improved digital presence[88].